| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper
|
Aapro, M.
|
|
|
22 |
2 |
p. 257-267
|
artikel
|
| 2 |
A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck
|
Won, Y.-W.
|
|
|
22 |
2 |
p. 417-423
|
artikel
|
| 3 |
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study
|
Biagi, J.J.
|
|
|
22 |
2 |
p. 335-340
|
artikel
|
| 4 |
A review of PARP inhibitors: from bench to bedside
|
Underhill, C.
|
|
|
22 |
2 |
p. 268-279
|
artikel
|
| 5 |
Associations of various gene polymorphisms with toxicity in colorectal cancer patients receiving oral uracil and tegafur plus leucovorin: a prospective study
|
Tsunoda, A.
|
|
|
22 |
2 |
p. 355-361
|
artikel
|
| 6 |
Barriers and facilitators to chemotherapy patients’ engagement in medical error prevention
|
Schwappach, D.L.B.
|
|
|
22 |
2 |
p. 424-430
|
artikel
|
| 7 |
Breast cancer incidence and time trend in France from 1990 to 2007: a population-based study from two French cancer registries
|
Daubisse-Marliac, L.
|
|
|
22 |
2 |
p. 329-334
|
artikel
|
| 8 |
Chronic non-communicable diseases, the European Chronic Disease Alliance—and cancer
|
Senn, H.-J.
|
|
|
22 |
2 |
p. 248-249
|
artikel
|
| 9 |
Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors
|
Boss, D.S.
|
|
|
22 |
2 |
p. 431-437
|
artikel
|
| 10 |
Clinical validation of an autoantibody test for lung cancer
|
Boyle, P.
|
|
|
22 |
2 |
p. 383-389
|
artikel
|
| 11 |
Comparison of four prognostic scores in peripheral T-cell lymphoma
|
Gutiérrez-García, G.
|
|
|
22 |
2 |
p. 397-404
|
artikel
|
| 12 |
Correction to: Chronic lymphocytic leukemia
|
|
|
|
22 |
2 |
p. 492
|
artikel
|
| 13 |
Correlation of basal EGFR expression with pancreatic cancer grading but not with clinical outcome after gemcitabine-based treatment
|
Funel, N.
|
|
|
22 |
2 |
p. 482-484
|
artikel
|
| 14 |
Dietary folate intake and the risk of 11 types of cancer: a case–control study in Uruguay
|
Aune, D.
|
|
|
22 |
2 |
p. 444-451
|
artikel
|
| 15 |
Dietary quercetin intake and risk of gastric cancer: results from a population-based study in Sweden
|
Ekström, A.M.
|
|
|
22 |
2 |
p. 438-443
|
artikel
|
| 16 |
Editorial Board
|
|
|
|
22 |
2 |
p. ii-iii
|
artikel
|
| 17 |
Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma
|
Sandlund, J.T.
|
|
|
22 |
2 |
p. 468-471
|
artikel
|
| 18 |
Histotype predicts the curative potential of radiotherapy: the example of ovarian cancers
|
Swenerton, K.D.
|
|
|
22 |
2 |
p. 341-347
|
artikel
|
| 19 |
Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up
|
Penel, N.
|
|
|
22 |
2 |
p. 452-457
|
artikel
|
| 20 |
Immunoglobulin D multiple myeloma: response to therapy, survival, and prognostic factors in 75 patients
|
Kim, M.K.
|
|
|
22 |
2 |
p. 411-416
|
artikel
|
| 21 |
Infusion reactions to the chimeric EGFR inhibitor cetuximab—change to the fully human anti-EGFR monoclonal antibody panitumumab is safe
|
Resch, G.
|
|
|
22 |
2 |
p. 486-487
|
artikel
|
| 22 |
Integrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial
|
von Minckwitz, G.
|
|
|
22 |
2 |
p. 301-306
|
artikel
|
| 23 |
Internet to boost patient accrual in oncology trials? A multiinstitutional AERIO study
|
Rodrigues, M.J.
|
|
|
22 |
2 |
p. 490-491
|
artikel
|
| 24 |
KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: Does treatment combination partner matter?
|
Zhang, W.
|
|
|
22 |
2 |
p. 484-485
|
artikel
|
| 25 |
Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy
|
Guiu, S.
|
|
|
22 |
2 |
p. 321-328
|
artikel
|
| 26 |
Merkel cell carcinoma, chronic lymphocytic leukemia and other lymphoproliferative disorders: an old bond with possible new viral ties
|
Tadmor, T.
|
|
|
22 |
2 |
p. 250-256
|
artikel
|
| 27 |
Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b–based chemoradiation: ACOSOG Trial Z05031
|
Picozzi, V.J.
|
|
|
22 |
2 |
p. 348-354
|
artikel
|
| 28 |
Phase II study of helical tomotherapy for oligometastatic colorectal cancer
|
Engels, B.
|
|
|
22 |
2 |
p. 362-368
|
artikel
|
| 29 |
Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer
|
Frederiksen, C.
|
|
|
22 |
2 |
p. 369-375
|
artikel
|
| 30 |
Positron emission tomography/computed tomography in the management of recurrent/metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital
|
Constantinidou, A.
|
|
|
22 |
2 |
p. 307-314
|
artikel
|
| 31 |
Posterior reversible encephalopathy syndrome in childhood cancer
|
de Laat, P.
|
|
|
22 |
2 |
p. 472-478
|
artikel
|
| 32 |
Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma
|
Patil, S.
|
|
|
22 |
2 |
p. 295-300
|
artikel
|
| 33 |
Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]
|
Albers, P.
|
|
|
22 |
2 |
p. 288-294
|
artikel
|
| 34 |
Randomized phase III trials of second-line chemotherapy in patients with advanced bladder cancer: progress and pitfalls
|
Bellmunt, J.
|
|
|
22 |
2 |
p. 245-247
|
artikel
|
| 35 |
Receptor status (ER, PgR and HER2) discordance between primary tumor and locoregional recurrence in breast cancer
|
Zurrida, S.
|
|
|
22 |
2 |
p. 479-480
|
artikel
|
| 36 |
Synovial sarcomas usually metastasize after >5 years: a multicenter retrospective analysis with minimum follow-up of 10 years for survivors
|
Krieg, A.H.
|
|
|
22 |
2 |
p. 458-467
|
artikel
|
| 37 |
Table of Contents
|
|
|
|
22 |
2 |
p. iv-vi
|
artikel
|
| 38 |
The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG–PET or gallium-67 scans
|
Dorth, J.A.
|
|
|
22 |
2 |
p. 405-410
|
artikel
|
| 39 |
Thrombotic microangiopathy related to anti-VEGF agents: intensive versus conservative treatment?
|
Izzedine, H.
|
|
|
22 |
2 |
p. 487-490
|
artikel
|
| 40 |
Time trend in treatment-related deaths of patients with advanced non-small-cell lung cancer enrolled into phase III trials of systemic treatment
|
Fujiwara, Y.
|
|
|
22 |
2 |
p. 376-382
|
artikel
|
| 41 |
Total recall of radiotherapy with mTOR inhibitors: a novel and potentially frequent side-effect?
|
Bourgier, C.
|
|
|
22 |
2 |
p. 485-486
|
artikel
|
| 42 |
Unfavorable prognosis of elderly patients with early-stage extranodal nasal-type NK/T-cell lymphoma
|
Wang, Z.Y.
|
|
|
22 |
2 |
p. 390-396
|
artikel
|
| 43 |
Updating progress in sarcoma therapy with mTOR inhibitors
|
Blay, J.-Y.
|
|
|
22 |
2 |
p. 280-287
|
artikel
|
| 44 |
Validation of the Institut Curie simplified prognostic score for breast cancer meningeal carcinomatosis
|
Bidard, F.-C.
|
|
|
22 |
2 |
p. 480-482
|
artikel
|
| 45 |
Weekly combination of non-pegylated liposomal doxorubicin and taxane in first-line breast cancer: wALT trial (phase I–II)
|
Rosati, M.S.
|
|
|
22 |
2 |
p. 315-320
|
artikel
|
Tijdschrift beschrijving